Cocrystal Pharma Provides Business Update and Reports Third Quarter 2026 Financial Results
Completed dosing in Phase 1b challenge study of CDI-988 for norovirus prevention and treatment with no serious adverse events reportedPreliminary efficacy results expected near the end of 2026 Closed $5 million private placement with OPKO HealthAppointed antiviral drug development leader Carol Brosgart, MD, to the Board of Directors BOTHELL, Wash., Nov. 15, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) provides updates on its antiviral product pipe
Completed dosing in Phase 1b challenge study of CDI-988 for norovirus prevention and treatment with no serious adverse events reportedPreliminary efficacy results expected near the end of 2026 Closed $5 million private placement with OPKO HealthAppointed antiviral drug development leader Carol Brosgart, MD, to the Board of Directors BOTHELL, Wash., Nov. 15, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) provides updates on its antiviral product pipe
What's Your Reaction?
